NCT06492512 Oral Iron Supplementation on Alternate vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy
| NCT ID | NCT06492512 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Southern Illinois University |
| Condition | Iron-deficiency Anemia (IDA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-05-27 |
| Primary Completion | 2028-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 120 participants in total. It began in 2025-05-27 with a primary completion date of 2028-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This will be a randomized clinical trial. Enrolled subjects will be randomized (1:1) into two study arms to receive either daily (Group 1) or alternate day (Group 2) supplementation with one oral pill containing ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill.
Eligibility Criteria
Inclusion Criteria: * Pregnant patients will be enrolled at less than 30 weeks gestational age (GA) with laboratory confirmed IDA (as defined by hemoglobin under 10.5 g/dL, as well as ferritin under 15 mcg/L) Exclusion Criteria: * Patients \<18 years old, patients who have severe IDA that requires blood transfusion or IV iron infusion, patients who have other known hemoglobinopathy (such as thalassemia or sickle cell anemia) or anemia of different mechanism (such as vitamin B12 or folate deficiency), patients with ulcerative colitis, Crohn's disease, gastric ulcers, patients who have previously undergone gastric bypass surgery, patients who experience admission for antepartum bleed, have been diagnosed with abnormal placentation (i.e., placenta previa, placenta accreta, placenta increta or percreta)
Contact & Investigator
Yahia Zeino, MD
PRINCIPAL INVESTIGATOR
Southern Illinois University School of Medicine
Frequently Asked Questions
Who can join the NCT06492512 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Iron-deficiency Anemia (IDA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06492512 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06492512 currently recruiting?
Yes, NCT06492512 is actively recruiting participants. Contact the research team at kgroesch@siumed.edu for enrollment information.
Where is the NCT06492512 trial being conducted?
This trial is being conducted at Springfield, United States.
Who is sponsoring the NCT06492512 clinical trial?
NCT06492512 is sponsored by Southern Illinois University. The principal investigator is Yahia Zeino, MD at Southern Illinois University School of Medicine. The trial plans to enroll 120 participants.